Enterprise Value
7.011M
Cash
24.64M
Avg Qtr Burn
-5.419M
Short % of Float
0.16%
Insider Ownership
0.72%
Institutional Own.
31.31%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NUC-7738 (ProTide) Details Solid tumor/s, Cancer, Melanoma | Phase 2 Data readout | |
NUC-3373 (ProTide) combo w/ irinotecan/bevacizumab/oxaliplatin Details Colorectal cancer , Cancer | Phase 2 Data readout | |
NUC-3373 (ProTide) combo w/ pembrolizumab Details Solid tumor/s, Cancer, Lung cancer | Phase 1/2 Data readout | |
Acelarin (NUC-1031) (dFdCTP) Details Cancer, Biliary Tract Cancer | Failed Discontinued |